Growth fact(or)s

Scheduled market launch in USA, Australia, Brazil

–

MDSAP(Medical Devise Single Audit Program)-certification including ISO 13485:2016

–

botiss participation at 3 ITI congresses

–

Fourth bone & tissue days world congress

CE mark approval permamem® and cerabone®

–

botiss participation at ITI World Symposium in Basel

Third bone & tissue days in Berlin

–

Pre-launch of first products in the USA

–

Straumann takes over exclusive distribution of botiss products in Germany

Market launch of maxgraft® cortico

–

botiss participation at 8 ITI congresses worldwide

Pharmaceutical approval for maxgraft® and for maxgraft® bonebuilder

–

Second bone & tissue days in Berlin with 800 participants

–

Worldwide cooperation with Straumann in the field of regenerative products

Exclusive cooperation with the Charité tissue bank for the dental regeneration

First bone & tissue days in Berlin

CE mark approval for mucoderm® and for maxresorb® inject

–

Acquisition of Cells+Tissubank Austria

CE mark approval for collprotect® membrane

CE mark approcal for Jason® membrane

Establishment of botiss medical AG

CE mark approval for maxresorb®